Cala

Cala Health is a commercial-stage bioelectronic medicine company transforming the care of patients with chronic disorders through wearable neuromodulation therapies. The company's lead product, Cala kIQ, is an FDA-cleared wearable device that delivers non-invasive Transcutaneous Afferent Patterned Stimulation (TAPS) to treat essential tremor and Parkinson's disease tremor. By targeting the central tremor network through peripheral nerves, Cala provides a non-pharmacological alternative to traditional medications and invasive surgeries. The company is expanding its platform to address other indications in neurology, cardiology, and psychiatry.